Eli Lilly's Q3 sales jump 39% as company lifts full-year outlook
Eli Lilly's third-quarter sales climbed 39% to $24.4 billion, and the drugmaker raised its 2026 revenue and profit forecasts, per a TradingView summary of SEC filings.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Eli Lilly posted third-quarter revenue of $24.4 billion, a 39% gain from the $17.6 billion recorded a year earlier. Adjusted earnings per share reached $7.48, up 7%, while net income rose 16% to $6.45 billion. Growth was driven mainly by Mounjaro and Zepbound, with the newly launched Foundayo also contributing.
The company now expects 2026 revenue of $91 billion to $92 billion and adjusted EPS between $35.00 and $36.00. Other developments in the period included several FDA approvals and positive Phase 3 data for retatrutide against Ozempic at 2 mg.
why it matters
Strong sales growth and a higher forecast support investor interest in the pharmaceutical sector and large healthcare companies. The figures come from an AI-generated summary of SEC filings, so they should be checked against the original documents.
market impact
LLY and US healthcare: strong sales and a raised forecast support the shares and the sector
- Eli Lilly shares pressure up — a raised forecast and revenue growth support demand for the stock
tags
instruments
sources
- Eli Lilly Q3 Revenue Rises 39% to $24.4 Billion, Raises 2026 Guidance — TradingView, 29 October 2026 at 11:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗